



IFW

PATENT
Attorney Docket 053529-5007-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Berkley Lynch *et al.***)
)
Application No. **10/537,512**) Group Art Unit: *Unassigned*
)
Filing Date: **June 3, 2005**) Examiner: *Unassigned*
)
For: **Methods for the Identification of Agents**)
 for the Treatment of Seizures,)
 Neurological Diseases, Endocrinopathies)
 and Hormonal Diseases)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

The present application is a U.S. National Phase Application of International Application No. PCT/US2003/038122, filed December 2, 2003 and published June 17, 2004 as WO 2004/051222 A2. Attached hereto is a copy of the International Search Report for PCT application PCT/US03/038112. Each of the documents cited on the International Search Report is listed on the attached Form PTO-1449 or on a previously submitted Form PTO-1449.

With the exception of a published U.S. Patent application, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there are any additional fees due in connection with the filing of this Information Disclosure Statement, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. §1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Dated: May 4, 2006

MORGAN, LEWIS & BOCKIUS LLP

Morgan, Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue

Washington, D.C. 20004

Phone: (202)-739-3000

By: 

Sally P. Teng

Registration No. 45,397

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket No.

053529-5007-02

Application No 10/537,512

Applicants: Berkley LYNCH *et al.*

PAGE 1 of 1

Filing Date: June 3, 2005

Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
	US 2002/0082252	06/27/2002	Hochman	514	214	1/23/2002

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Sub-Class	Translation
WO 01/39779	11/27/2000	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Sigma (2003) Product Information for n-Docedul beta-D-maltoside, Product Number D4641

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.